Overview: Pfizer stock is trading near $25.86 with moderate upside potential based on the forecast range of up to ...

Pfizer has fallen behind the pack when it comes to GLP-1 drugs, but the company is still fighting.

Pfizer Inc. (PFE) shares are trading higher on Tuesday, as the stock benefits from a price target increase at Cantor ...

Pfizer has lagged the broader market over the past year, and analysts remain cautious about its future outlook.

Pfizer may look cheap with a ~7% yield, but tight free cash flow, patent cliffs, and limited growth raise downside risk. Read ...

PFE heads into Q4 earnings with strong oncology and Vyndaqel demand, but IRA headwinds, COVID declines and falling estimates ...

Pfizer Inc. has a rare 3-year tariff exemption and margin defense amid global price parity risks. Click here to read an ...

Analysts expect the New York-based company to report quarterly earnings at 57 cents per share, down from 63 cents per share ...

If you like dividend stocks, here's a high yielder, a Dividend King, and a turnaround story to consider as January comes to a ...

That said, let's consider three stocks yielding well above 4% that income-oriented investors should consider: Pfizer ( PFE +1 ...

As of Wednesday, January 28, Relay Therapeutics, Inc.’s RLAY share price has dipped by 5.18%, which has investors questioning if this is right time to buy.

Detailed price information for Summit Therapeu ADR (SMMT-Q) from The Globe and Mail including charting and trades.